secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0000929638-26-001150
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents Q4/FY2025: Revenue $37.1M (+4% YoY), net loss improves to $8.2M; targets H2 2026 cash breakeven
--------------------------------------------------------------------------------

- Revenue $37.1M (+4% YoY); gross margin 71%. Net loss improved to $8.2M ($0.13/sh) from $20.7M loss.
- Adjusted net loss $14.2M ($0.23/sh) flat per share; adjusted EBITDA loss $10.5M improved from $11.5M.
- Cash $7.8M at Dec 31, 2025; amended credit facility added $2.5M; workforce reduced 10% in Q4.
- Targets cash flow breakeven in H2 2026; ongoing FDA discussions for DrugSorb-ATR De Novo submission (timing TBD).
- Direct sales outside Germany +13%, distributor sales +11.4%; Germany sales -10% due to restructuring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000092963826001150/0000929638-26-001150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000092963826001150/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-26-001150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer